Clicky

Allakos Inc.(ALLK)

Description: Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.


Keywords: Medicine Biotechnology Biology Disease Immunology Immune System Antibodies Inflammation Antibody Cell Biology Allergy Allergic Conjunctivitis Mastocytosis Systemic Mastocytosis Eosinophil Mast Cell Urticaria

Home Page: www.allakos.com

ALLK Technical Analysis

975 Island Drive
Redwood City, CA 94065
United States
Phone: 650 597 5002


Officers

Name Title
Dr. Robert Alexander Ph.D. CEO & Director
Dr. Adam L. Tomasi Ph.D. Pres & COO
Mr. Baird Radford III Chief Financial Officer
Dr. Henrik Sandvad Rasmussen Strategic Advisor
Dr. Craig Paterson M.D. Chief Medical Officer
Brad Youngblood Head of Research
Mr. Alan Chang Director of Medical Affairs & Data Analytics

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.8517
Price-to-Sales TTM: 0
IPO Date: 2018-07-19
Fiscal Year End: December
Full Time Employees: 192
Back to stocks